Protein expression of Fas, Fas ligand, Bcl-2 and TGFβ2 and correlation with survival in initial and recurrent human gliomas

Journal of Neuro-Oncology

Volumn 67, Issue 1-2, 2004, Pages 29-39

  Strege, Rainer J ^a,b   Godt, Christian ^a   Stark, Andreas M ^a   Hugo, Heinz Hermann ^a   Mehdorn, H Maximilian ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Klinikum Plau am See   (Germany)

Author keywords

Astrocytoma; B cell lymphoma leukemia 2 (Bcl 2); Expression; Fas (CD 95 antigen); Fas ligand (FasL); Glioblastoma; Survival; Transforming growth factor 2(TGF 2)

Indexed keywords

CARBOPLATIN; CARMUSTINE; FAS ANTIGEN; FAS LIGAND; PROTEIN BCL 2; TAMOXIFEN; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA2;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CRANIOTOMY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; STATISTICAL ANALYSIS; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD95; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FAS LIGAND PROTEIN; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; TUMOR MARKERS, BIOLOGICAL;

EID: 1842536981     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000021739.34343.75     Document Type: Article

References (38)

1. Parney IF, Hao C, Petruk KC: Glioma immunology and immunotherapy. Neurosurgery 46: 778-792, 2000
2. Schmitt CA, Lowe SW: Apoptosis and therapy. J Pathol 187: 127-137, 1999
3. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991
4. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993
5. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181: 71-77, 1995
6. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY: Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99: 1173-1178, 1997
7. Didenko VV, Hop NN, Candace M, Baskin DS: Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg 96: 580-584, 2002
8. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 3: 614-620, 1997
9. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X: Bid, a BCL 2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998
10. Massagué J: The TGF-beta family of growth and differentiation factors. Cell 49: 437-438, 1987
11. Frankel B, Longo SL, Ryken TC: Human astrocytomas co-expressing Fas and Fas ligand also produce TGFβ2 and Bcl-2. J Neuro-Oncol 44: 205-212, 1999
12. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2002
13. Scherer HJ: Cerebral astrocytomas and their derivatives. Am J Cancer 40: 159-198, 1940
14. Husain N, Chiocca EA, Rainov N, Louis DN, Zervas NT: Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol 95: 287-290
15. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H: Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7: 863-869, 1997
16. Krishna M, Smith TW, Recht LD: Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. J Neurosurg 83: 1017-1022, 1995
17. Hara A, Hirose Y, Yoshimi N, Tanaka T, Mori H: Expression of Bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors. Neurol Res 19: 623-628
18. Delgado MB, Anderson JR, Whittle IR, Wharton SB: Expression of Bcl-2 and Bax in oligodendrogliomas and their relationship to apoptosis. Neuropathol Appl Neurobiol 25: 400-407, 1999
19. Ehrmann J Jr, Rihakova P, Hlobilkova A, Kala M, Kolar Z: The expression of apoptosis-related proteins and the apoptotic rate in glial tumors of the brain. Neoplasma 47 (Suppl 3): 151-155, 2000
20. Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J: Bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol (Berl) 88: 520-526, 1994
21. Ehrmann J Jr, Kolar Z, Vojtesek B, Kala M, Komenda S, Oulton A: Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma 44: 299-304, 1997
22. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC: Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150: 805-814, 1997
23. Martin S, Toquet C, Oliver L, Cartron PF, Perrin P, Meflah K, Cuillère P, Vallette FM: Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal. J Neuro-Oncol 52: 129-139, 2001
24. Frankel B, Longo SL, Ryken TC: Co-expression of Fas and Fas ligand in human non-astrocytic glial tumors. Acta Neuropathol 98: 363-366, 1999
25. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 55: 5528-5530, 1995
26. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643, 1995
27. Frankel B, Longo SL, Leach C, Canute GW, Ryken TC: Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression. J Neuro-Oncol 59: 27-34, 2002
28. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science: 263: 1759-1762, 1994
29. Streffer JR, Schuster M, Zipp F, Weller M: Soluble CD95 (Fas/APO-1) in malignant glioma: (No) implications for CD95-based immunotherapy? J Neuro-Oncol 40: 233-235, 1998
30. Hamel W, Westphal M: Growth factors in gliomas revisited. Acta Neurochir 142: 113-138, 2000
31. Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiadò-Piat L: Bcl-2 distribution in neuroepithelial tumors: an imunohistochemical study. J Neuro-Oncol 27: 101-109, 1996
32. Shinoura N, Yoshida Y, Nishimura M, Muramatsu Y, Asai A, Kirino T, Hamada H: Expression level of Bcl-2 determines anti- or proapoptotic function. Cancer Res 59: 4119-4128, 1999
33. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M, Meyermann R: BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 67: 763-768
34. Stark AM, Hugo HH, Witzel P, Mihajlovic Z, Mehdorn HM: Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir 64: 30-36, 2003
35. Stark AM, Witzel P, Strege RJ, Hugo H-H, Mehdorn HM: p53, mdm2, EGFR and msh2 expression in paired initial and recurrent glioblastoma multiforme. J Neurol Neurosurg Psychiatry 74: 779-783, 2003
36. Newcomb EW, Balla SK, Parrish CL, Hayes RL, Cohen H, Miller DC: bcl-2 protein expression in astrocytomas in relation to patient survival and p 53 gene status. Acta Neuropathol (Berl) 94: 369-375, 1997
37. Korshunov A, Golanov A, Sycheva R, Pronin I: Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol 52: 574-580, 1999
38. Fels C, Schäfer C, Hüppe B, Bahn H, Heidecke V, Kramm CM, Lautenschläger C, Rainov NG: Bcl-2 expression in higher-grade human glioma: a clinical and experimental study. J Neuro-Oncol 48: 207-216, 2000